Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim Expanded Access in NHL
NCT02782845Phase 4Completed
- Sponsor
- Roche
- Start
- Jun 2006
- Primary completion
- Oct 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of pegfilgrastim in neutropenia, sponsored by Roche. Primary endpoint: Percentage of Participants with Febrile Neutropenia and/or Grade IV Neutropenia in Cycle 1. Started Jun 2006; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02782845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02782845.